These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8396098)

  • 1. Pharmacokinetics of azithromycin in patients with impaired hepatic function.
    Mazzei T; Surrenti C; Novelli A; Crispo A; Fallani S; Carlà V; Surrenti E; Periti P
    J Antimicrob Chemother; 1993 Jun; 31 Suppl E():57-63. PubMed ID: 8396098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of dirithromycin in patients with mild or moderate cirrhosis.
    Mazzei T; Surrenti C; Novelli A; Biagini MR; Fallani S; Cassetta MI; Conti S; Surrenti E
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1556-9. PubMed ID: 10390202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin.
    Cooper MA; Nye K; Andrews JM; Wise R
    J Antimicrob Chemother; 1990 Oct; 26(4):533-8. PubMed ID: 2174853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azithromycin pharmacokinetics and penetration to lymph.
    Bergan T; Jørgensen NP; Olszewski W; Zhang Y
    Scand J Infect Dis Suppl; 1992; 83():15-21. PubMed ID: 1336891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the pharmacokinetics of three-day and five-day regimens of azithromycin in plasma and urine.
    Wildfeuer A; Laufen H; Leitold M; Zimmermann T
    J Antimicrob Chemother; 1993 Jun; 31 Suppl E():51-6. PubMed ID: 8396097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open study to compare the pharmacokinetics, safety and tolerability of a multiple-dose regimen of azithromycin in young and elderly volunteers.
    Coates P; Daniel R; Houston AC; Antrobus JH; Taylor T
    Eur J Clin Microbiol Infect Dis; 1991 Oct; 10(10):850-2. PubMed ID: 1662630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
    Baririan N; Van Obbergh L; Desager JP; Verbeeck RK; Wallemacq P; Starkel P; Horsmans Y
    Clin Pharmacokinet; 2007; 46(3):261-70. PubMed ID: 17328584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of azithromycin in rats and dogs.
    Shepard RM; Falkner FC
    J Antimicrob Chemother; 1990 Jan; 25 Suppl A():49-60. PubMed ID: 2154438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of azithromycin after single oral dosing of experimental animals.
    Davila D; Kolacny-Babić L; Plavsić F
    Biopharm Drug Dispos; 1991 Oct; 12(7):505-14. PubMed ID: 1657238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of diacerein in patients with liver cirrhosis.
    Magnard O; Louchahi K; Tod M; Petitjean O; Molinier P; Berdah L; Perret G
    Biopharm Drug Dispos; 1993 Jul; 14(5):401-8. PubMed ID: 8218958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of dirithromycin in patients with impaired hepatic function.
    LaBreque D; Johlin F; Janda R; Shreves T; Gereats D; DeSante K; Cerimele B; Lanier T; Sides G
    J Antimicrob Chemother; 1993 Nov; 32(5):741-50. PubMed ID: 8125838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of ciprofloxacin in impaired liver function.
    Esposito S; Miniero M; Barba D; Sagnelli E
    Int J Clin Pharmacol Res; 1989; 9(1):37-41. PubMed ID: 2707924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics of azithromycin in human serum and tissues.
    Foulds G; Shepard RM; Johnson RB
    J Antimicrob Chemother; 1990 Jan; 25 Suppl A():73-82. PubMed ID: 2154441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics of azithromycin and their clinical significance.
    Lode H
    Eur J Clin Microbiol Infect Dis; 1991 Oct; 10(10):807-12. PubMed ID: 1662623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and bioavailability of ranitidine in normal subjects and cirrhotic patients.
    Morichau-Beauchant M; Houin G; Mavier P; Alexandre C; Dhumeaux D
    Dig Dis Sci; 1986 Feb; 31(2):113-8. PubMed ID: 3943439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single dose pharmacokinetics of manidipine in hepatic impaired patients and healthy controls.
    Deroubaix X; Lins RL; Lens S; Allemon A; Jeanbaptiste B; Poli G; Acerbi D; Stockis A; Ventura P
    Int J Clin Pharmacol Ther; 1998 Jul; 36(7):386-91. PubMed ID: 9707354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension.
    Nahata MC; Koranyi KI; Gadgil SD; Hilligoss DM; Fouda HG; Gardner MJ
    Antimicrob Agents Chemother; 1993 Feb; 37(2):314-6. PubMed ID: 8383944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concentration of azithromycin in human prostatic tissue.
    Foulds G; Madsen P; Cox C; Shepard R; Johnson R
    Eur J Clin Microbiol Infect Dis; 1991 Oct; 10(10):868-71. PubMed ID: 1722460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gynaecological tissue levels of azithromycin.
    Krohn K
    Eur J Clin Microbiol Infect Dis; 1991 Oct; 10(10):864-8. PubMed ID: 1662635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.